Vimarsana
Biggest News Aggregation in the World

Page 41 - Bio Developments News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bio Developments. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bio Developments Today - Breaking & Trending Today

TrakCel's Matthew Lakelin: 'We don't want to have wonderful, curative treatments and some people not wanting to take them' - Vimarsana News

TrakCel's Matthew Lakelin: 'We don't want to have wonderful, curative treatments and some people not wanting to take them'

TrakCel is a provider of integrated cellular orchestration solutions for the management, control and tracking of cell and gene therapy products.

Interview: TrakCel's Matthew Lakelin on new wave of therapeutic treatments - Vimarsana News

Interview: TrakCel's Matthew Lakelin on new wave of therapeutic treatments

TrakCel is a provider of integrated cellular orchestration solutions for the management, control and tracking of cell and gene therapy products.

Moderna's updated COVID-19 vaccine receives positive CHMP opinion - Vimarsana News

Moderna's updated COVID-19 vaccine receives positive CHMP opinion

Moderna has revealed that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for Spikevax, its updated COVID-19 vaccine.

LabGenius' research collaboration with Sanofi yields positive results - Vimarsana News

LabGenius' research collaboration with Sanofi yields positive results

LabGenius, a company focused on machine learning (ML) for antibody discovery, has presented key data in a poster presentation at the Single-Domain Antibodies 2023 Meeting.

Veeva Summit: Why Takeda is taking ownership of its technology - Vimarsana News

Veeva Summit: Why Takeda is taking ownership of its technology

Global biopharmaceutical company Takeda is working to modernize its operations in order to better serve clinical trial sites, patients and sponsor outcomes.